XOMA Royalty Says Zevra Therapeutics Received FDA Approval For MIPLYFFA; Says It Is Entitled To Receive Mid-single Digit Royalty On MIPLYFFA Sales And Up To $52.6M In Milestones
XOMA Royalty Says Zevra Therapeutics Received FDA Approval For MIPLYFFA; Says It Is Entitled To Receive Mid-single Digit Royalty On MIPLYFFA Sales And Up To $52.6M In Milestones
XOMA版稅表示Zevra Therapeutics獲得了MIPLYFFA的FDA批准；表示有權獲得MIPLYFFA銷售中的中等個位數版稅，並且有資格獲得高達5260萬美元的里程碑獎勵
XOMA Royalty Says Zevra Therapeutics Received FDA Approval For MIPLYFFA; Says It Is Entitled To Receive Mid-single Digit Royalty On MIPLYFFA Sales And Up To $52.6M In Milestones
XOMA版稅表示Zevra Therapeutics獲得了MIPLYFFA的FDA批准；表示有權獲得MIPLYFFA銷售中的中等個位數版稅，並且有資格獲得高達5260萬美元的里程碑獎勵
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。